Kornimate/medical-research-clean huggingface dataset:
effectiveness of using tobacco free snuff in reducing negative effects of smokeless tobacco use

Conditions: Tobacco Use Disorder

Summary: though spit tobacco is smokeless, it still affects the cardiovascular system and may be associated with heart disease, stroke, and high blood pressure. long-term effects of smokeless tobacco (st) include tooth abrasion, gum recession, mouth disease, loss of bone in the jaw, yellowing of teeth, and chronic bad breath. this study will assess the effectiveness of using tobacco free snuff in reducing levels of exposure to tobacco and associated toxicity, as well as enhancing motivation to either quit or sustain lower levels of nicotine intake.

spit tobacco presents as many health risks to its users as smoking tobacco. although a significant number of st users recognize the importance of quitting, many either do not want to quit or feel it is impossible. for these individuals, tobacco reduction may be an important transitional goal, either prior to quitting or as a treatment endpoint. however, approaches to help st users reach this goal have not been studied. this study will assess the effectiveness of using tobacco-free snuff in reducing levels of exposure to tobacco and associated toxicity, as well as enhancing motivation to either quit or sustain lower levels of nicotine intake. participants will be randomly assigned to receive either treatment with tobacco-free snuff or treatment without it. all participants will be encouraged to reduce nicotine intake by 50% during the first four weeks and by 75% the following four weeks. participants receiving the tobacco-free snuff will be asked to alternate the use of their usual brand of st with tobacco-free snuff in order to achieve the targeted reduction. participants not receiving the tobacco-free snuff will only be informed to try to cut down their tobacco use to the targeted reduction. study visits will occur once weekly during the 8-week treatment period. assessments will include vital signs, physiological measures related to tobacco use, and measures of motivation and self-efficacy to quit st. the number of participants who either do not complete treatment, reduce nicotine intake, or quit completely will be assessed at the week 8 study visit and at follow-up visits, which will be held at weeks 12 and 26.

Eligibility criteria:
inclusion criteria: * not interested in quitting smokeless tobacco use within 90 days of study entry * used smokeless tobacco at least six times a day for 6 months prior to study entry * agree to use an effective form of contraception throughout the study exclusion criteria: * current use of tobacco or nicotine products other than st * pregnant or breastfeeding * any unstable medical condition * use of any medication that may affect tobacco use or be affected by reduction of tobacco use * dsm-iv diagnosis of any psychiatric disorders or substance abuse disorders within 6 months prior to study entry * use of any psychotropic medications within 6 months prior to study entry

Keywords: smokeless tobacco, harm reduction
studying mechanisms of radiation therapy resistance in samples from younger patients with rhabdomyosarcoma

Conditions: Alveolar Childhood Rhabdomyosarcoma; Embryonal Childhood Rhabdomyosarcoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Untreated Childhood Rhabdomyosarcoma; Recurrent Childhood Rhabdomyosarcoma

Summary: this laboratory study is looking into mechanisms of radiation therapy resistance in samples from younger patients with rhabdomyosarcoma. studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors find better ways to treat cancer

observational study model: cohort time perspective: retrospective biospecimen retention: samples with dna biospecimen description: tissue study population description: primary care clinic sampling method: non-probability sample objectives: i. determine the molecular response/resistance signatures with radiotherapy and standard chemoradiation treatments using the xenograft model of the pediatric preclinical testing program (pptp). ii. validate these novel pathways/biomarkers by their detection within clinically annotated patient tumor tissue samples and testing their associations with clinical response, local control rates, and overall survival rates. outline: archived tissue samples of matched primary-relapsed and non-matched primary are analyzed for genomic dna, dna methylation profiles, rna sequencing, differences between alveolar rhabdomyosarcoma (arms) and embryonal rhabdomyosarcoma (erms), gene expression profiles, target-of-rapamycin complex 1 (torc1) and torc2 pathway intermediates, and paired box 3 (pax3)/forkhead box o1 (foxo1) translocation by microarray, immunohistochemical staining, and fluorescence in situ hybridization (fish).

Eligibility criteria:
inclusion criteria: * tissues requested from the children oncology group (cog) sarcoma banking protocol cog-d9902 * all subtypes of rhabdomyosarcoma specimens * matched primary-relapsed specimens (from same patient, separated by time): * frozen tissue if available * scrolls of formalin-fixed paraffin-embedded tissue (if frozen not available) * 10 unstained formalin-fixed paraffin-embedded thin sections * all other general (primary or relapsed) cases * 10 unstained formalin-fixed paraffin-embedded thin sections
trial comparing efficacy of treatments for hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: the purpose of this research study is to further evaluate the efficacy of two treatment regimens for the treatment of hidradenitis suppurativa. this is a randomized controlled study. patients will be randomly assigned to an arm of the study.

histological studies suggest that hs is a disease of the follicles with apocrine involvement as a secondary event. the investigators have identified in a previous study that the nd yag laser is highly effective for decreasing the inflammation, pain, suppuration and frequency of recurrence of hs. oral antibiotic therapy with clindamycin and rifampin has also been reported in previous studies to be a highly effective treatment regimen for hs and is commonly used by physicians in medical management of hs. the investigators would like to compare the efficacy of ndyag laser treatment combined with antibiotics versus treatment with antibiotics alone. the goal is to evaluate the success of these two treatment regimens on existent hs lesions as well as prevention of recurrence. there will be approximately 18 people in this research study at henry ford health system (hfhs).

Eligibility criteria:
inclusion criteria: 1. be at least 16 years old and weigh a minimum of 80lbs. weight requirement is for the purpose of maintaining safe clindamycin and rifampin dosing regimens. 2. be otherwise healthy 3. have a diagnosis of hs 4. patients must have hurley stage ii hs, with one or more widely separated recurrent abscesses, with tract and scarring. involvement should be bilateral and symmetric on axillae, inguinal regions or inframammary regions 5. agree to abide by the investigator's guidelines regarding photosensitizing drugs 6. be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form 7. agree to follow and undergo all study-related procedures exclusion criteria: 1. patients with hs hurley stage i and iii will be excluded from participation in the study 2. patients who are currently pregnant will not be able to take part in the study due to the unknown effects of antibiotics 3. concomitant use of systemic or topical treatments for hs not involved in current study. patients must discontinue all forms of oral therapy as systemic and topical antibiotics and retinoids for 2 weeks prior to the start of any treatment 4. exacerbation of the patient's original condition expressed clinically by a shift from hurley stage ii to stage iii 5. patient is unable to take antibiotic therapy 6. any reason the investigator feels the patient should not participate in the study

Keywords: hidradenitis suppurativa antibiotics laser
home examinations researching and understanding submucosal evaluations

Conditions: Fertility Issues

Summary: to demonstrate that imaging via home ultrasound can identify submucosal fibroids. the image quality and submucosal fibroid detection specificity of the home imaging has already been demonstrated; the aim of this study is to generate further data for sensitivity. this will be a single visit study, with participants scanning themselves at home with healthcare professional (hcp) supervision. targeted population is women with previously diagnosed submucosal fibroids that have not been removed. the study will be single-blinded to the image raters.


Eligibility criteria:
inclusion criteria: * women with one or more submucosal fibroid, with appropriate attestation (see more detail below) * women between the ages of 18 and 49 inclusive (women 38 and younger can also receive their antral follicle count, or afc; 39 and older will participate in uterine scanning only) * women with bmi up to 40 * women located in states where the pi or sub-pi licensure is valid * women able to freely give consent electronically, given covid. for the purposes of this study, this is defined as women who speak native or fluent english; and have a high school degree or equivalent, and who are otherwise, in the professional judgement of the pi, able to give informed consent exclusion criteria: * women with expert ultrasound experience, e.g., ultrasound technologists, radiologists, ob/gyns, reproductive endocrinologists * women with bmi over 40 * women who do not speak english natively or fluently * women who have recently given birth, and have had fewer than 3 postpartum menstrual cycles * women who have recently had a stillbirth or abortion more than 20 weeks (subject to the 3 postpartum menstrual cycles above). miscarriages or abortions less than 20 weeks are subject to two wait cycles * women who are currently pregnant or may be pregnant * any woman the pi believes is not capable of giving independent, informed consent * turtle health employees
mesenchymal stem cells in critical limb ischemia

Conditions: Critical Limb Ischemia

Summary: this clinical trial aims to study the safety and efficacy of adult mesenchymal stem cells in critical limb ischemia.


Eligibility criteria:
inclusion criteria: * males or females with non-child bearing potential in the age group of 18-60 yrs of indian origin. * established cli, clinically and hemodynamically confirmed as per rutherford- ii-4, iii-5, or iii-6; patients having infra-inguinal arterial occlusive disease with rest pain or ischemic ulcer/necrosis, who are not eligible for or have failed traditional revascularization treatment (no option patients) * ankle brachial pressure index (abpi) ≤ 0.6 or ankle pressure ≤ 70 mm hg or tcpo2 ≤ 60 mmhg in the foot * patients if having associated type ii diabetes, should be on medication and well controlled (hba1c ≤ 8%) without complications * patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits * normal liver and renal function * on regular medication for hypertension if any exclusion criteria: * patients with cli suitable for surgical or percutaneous revascularization as determined by the surgeon performing vascular procedure and patients with any acute/chronic inflammatory condition * cli patient requiring amputation proximal to trans-metatarsal level * patients with gait disturbance for reasons other than cli. * type i diabetes * patients having respiratory complications/left ventricular ejection fraction \< 25%f) stroke or myocardial infarction within last 3 months * patients who are contraindicated for mra * have clinically serious and/or unstable inter-current infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the investigator, may be jeopardized by participation in this study or by the complications of this therapy * documented terminal illness or cancer or any concomitant disease process with a life expectancy of less than 1 year * patients already enrolled in another investigational drug trial or completed within 3 months. * history of severe alcohol or drug abuse within 3 months of screening. * hb% \ 8% * women with child bearing potential, pregnant and lactating women. * patients tested positive for hiv 1, hcv, hbv,

Keywords: mesenchymal stem cells critical limb ischemia
contrast-enhanced digital mammography(cedm) vs contrast-enhanced breast mri(ce-mri) in breast cancer

Conditions: Breast - Female

Summary: the primary objective is to determine how accurately one can estimate the size of the index tumor on preoperative imaging in patients with known breast cancer, using pathology as a reference standard. the primary endpoint, which will be measured on cedm,and ce-mri, is the maximum diameter (mm) of the index tumor.

the primary objective is to determine how accurately one can estimate the size of the index tumor on preoperative imaging in patients with known breast cancer, using pathology as a reference standard. the primary endpoint, which will be measured on cedm,and ce-mri, is the maximum diameter (mm) of the index tumor.

Eligibility criteria:
identify inclusion criteria 1. histologically confirmed invasive and/or in situ carcinoma of the breast 2. any race and ethnicity 3. females 18-70 years of age 4. willing and able to provide informed consent 5. subject will have a ce-mri exam within one month (31 days) of enrolling or has had a ce-mri exam within one month (31 days) prior to enrolling with no interval treatment or procedure between the cedm and ce-mri identify exclusion criteria 1. unwilling or unable to undergo informed consent 2. planned to undergo neoadjuvant chemotherapy 3. breast implants 4. pregnant (note: if subject is unsure of pregnancy status, a pregnancy test will be performed for confirmation.) 5. breast-feeding 6. surgical excision of the biopsy proven malignancy 7. known allergy to gadolinium contrast agents 8. contraindication for mri (ex: pacemaker, ferromagnetic aneurysm clips or other ferromagnetic surgical implant or severe claustrophobia) 9. suspected to be at risk to complications from the contrast agent. these include the standard iodinated contrast agent contraindications: 1. subject has renal insufficiency as determined by an elevated serum creatinine and is not being treated with dialysis. 2. documentation of a normal egfr (mdrd) within the previous 2 months will be required for any subject with any of the following risk factors for renal insufficiency: i. age \> 70 ii. diabetes iii. personal history of renal disease iv. family history of renal disease (e.g., polycystic kidney disease) v. known solitary kidney vi. other medical conditions that may affect the kidney (e.g., lupus, multiple myeloma) c. subject has taken metformin (glucophage) within 48 hours of procedure d. subject has had a prior reaction to iodinated contrast e. subject has multiple allergies and/ or severe asthma regularly treated with medication f. subject has had an episode of serious allergic reaction (anaphylaxis) to any substance
measurement of renal functional reserve

Conditions: Kidney Diseases

Summary: single arm physiological study to measure renal functional reserve as a biomarker of kidney function and health

the investigators will measure glomerular filtration rate using urinary clearance of cold iothalamate before and after an oral protein load in patients with chronic kidney disease and healthy volunteers.

Eligibility criteria:
inclusion criteria: 1. age ≥18 2. estimated gfr \>30 ml/min/1.73m2 exclusion criteria: 1. allergy to iothalamate, shellfish or iodine 2. use of metformin or amiodarone 3. inability to maintain a stable regimen of medications which affect gfr for \> one week prior to participation (e.g. non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, angiotensin receptor blockers) 4. use of medications which directly affect elimination of creatinine (e.g. cimetidine and trimethoprim) 5. acute exacerbation of asthma or chronic obstructive pulmonary disease within 3 months requiring hospitalization or oral steroid therapy 6. inadequate intravenous access 7. severe anemia (hct \<21%) 8. acute kidney injury (rise in creatinine to ≥1.5 times the previous baseline or by ≥ 0.3 mg/dl on most recent labs prior to enrollment) 9. history of contrast-induced nephropathy 10. hyperthyroidism 11. pheochromocytoma 12. sickle cell disease 13. urinary retention or incontinence 14. status post organ transplant 15. pregnancy or active breast feeding 16. cognitive impairment with inability to give consent 17. institutionalized status

Keywords: renal reserve, physiological study, diagnostic testing
electromyographic (emg) and mechanomyographic (mmg) comparison

Conditions: Stress Urinary Incontinence

Summary: the purpose of this study is to assess the delay between the detection (by mechanomyography-mmg) of rectus abdominis contraction and the detection of cough in cough effort.


Eligibility criteria:
inclusion criteria: * more or equal than 18 years old * patient affiliated to social security or similarly regime * healthy volunteer * bmi less than 30 exclusion criteria: * pregnant women and lactating mothers * ward of court or under guardianship * adult unable to express their consent or person under legal protection * person deprived of freedom by judicial or administrative decision * person hospitalized without their consent

Keywords: mechanography electromyography effort cough
the high density lipoprotein and endothelial function, niacin and nitric oxide study (the high-ennd study)

Conditions: Metabolic Syndrome

Summary: the aim of the present study is to characterize novel mechanisms whereby hdl may exert potent vasculoprotective effects independent of reverse cholesterol transport, in particular the effect of hdl on the regulation of the vascular nad(p)h oxidase enzyme system, a major vascular source of superoxide, known to be important for endothelial dysfunction. in addition, the present study will characterize the effect of hdl on endothelial progenitor cell (epc) mobilization, nitric oxide production and in vivo regenerative capacity.


Eligibility criteria:
inclusion criteria: * statin treatment for at least 3 weeks * reduced hdl: \< 40 mg/dl (1.03 mmol/l) in men or \< 50 mg/dl (1.29 mmol/l) in women * plus two of the following (thereby defining the patients to have metabolic syndrome (grundy et al.; circulation 2005)): * elevated waist circumference: ≥ 102 cm (≥ 40 inches) in men or ≥ 88 cm (≥ 35 inches) in women * elevated triglycerides: ≥ 150 mg/dl (1.7 mmol/l * elevated blood pressure: ≥ 130 mmhg systolic blood pressure or ≥ 80 mmhg diastolic blood pressure or anti-hypertensive treatment * elevated fasting glucose: ≥ 100 mg/dl or on drug treatment for elevated fasting glucose exclusion criteria: * hypersensitivity to niacin * active liver disease or impaired liver function * persistent elevation of transaminases * cholestasis * gastric ulcer * acute coronary syndrome * gout * pregnancy, lactation * active infections * cancer * untreated concomitant diseases * renal insufficiency or renal failure * hypothyreosis * alcoholism * myopathies * muscle pain under therapy with fibrates or statins * hereditary muscle diseases in family history

Keywords: metabolic syndrome high density lipoprotein extended-release niacin endothelial function endothelial progenitor cells
rehabilitation to patients over 65 years undergoing tha

Conditions: Hip Arthroplasty

Summary: patients over 65 years do not have a self care ability the surgery benefits them. the aim of this study is development of a rehabilitation program based on patients' self-rated health. 1. a cross section study including 600 patients 2. rct including 160 patients

fase 1: 600 patients waiting for or already having received total hip-/knee-replacement participated in a questionnaire study using sf- 36. the aim was to document self-rated health among this population. fase 2: results from the cross section study form the base for the rct, where 160 patients over 65 years undergoing thr, 80 patients are in an intervention group and 80 patients in a control group. a nurse intervention program is tested, and results from the study will form the base for a structured rehabilitation program.

Eligibility criteria:
inclusion criteria:patients over 65 years undergoing total hip replacement - exclusion criteria: * patients dropping out

Keywords: selfrated health, sf-36, rehabilitation, total hip replacement, patients above 65
fermented millet porridge, gut microbiota and inflammation status in women

Conditions: Inflammation; Microbiome, Human

Summary: maternal undernutrition concerns 10-19% of women of reproductive age globally, the vast majority of which live in sub saharan africa and south asia. recommendations for nutritional interventions to tackle the problem range from per-pregnancy supplementation to upstream interventions targeting women of reproductive age before conception. to render the latter interventions cost-effective and sustainable, experts recommend to focus on food processing that leads to an enhanced nutrient content. one such method, which has been known and practiced for centuries in diverse societies, is fermentation. traditionally fermented foods are diverse, widespread and highly appreciated in burkina faso. the present study aims to investigate the effect of fermented millet porridge on gut microbiota diversity, stool short chain fatty acid concentration and inflammation markers level in women of reproductive age living in rural burkina faso.


Eligibility criteria:
inclusion criteria: participant are * 18 to 49 years old * resident in the study area and do not plan to move within 5 months following the start of the study * are not on antibiotic treatment on inclusion and have not been in the previous 3 weeks. * do not suffer from any pathology that could interfere with their diet. * have no known allergy to pearl millet or its derivatives * agree to sign a consent to participate in the study- exclusion criteria: * women under 18 or over 49 * women not consuming pearl millet porridge due to allergy or food preference * women planning to move from the study area within 5 months of the start of the study * women with serious illnesses that may interfere with their diet * women on antibiotic treatment or at the time of inclusion or having been in the previous 3 weeks. * in addition, women who will benefit from antibiotic therapy during the study will be excluded from the analysis